CHATHAM, N.J., Nov. 13, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical ...

Analyst Rami Katkhuda of LifeSci Capital maintained a Buy rating on Eledon Pharmaceuticals (ELDN – Research Report), retaining the price ...

Tonix's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting ...

Completed enrollment of Phase 2 BESTOW trial of tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline results in fourth quarter of 2025 Announced positive ini ...

Completed enrollment of Phase 2 BESTOW trial of tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline ...

Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Guggenheim ...

Detailed price information for Tonix Pharm Holdings (TNXP-Q) from The Globe and Mail including charting and trades.

研究表明，阻断CD40L能够抑制多种共同刺激受体，包括CD40和CD11的激活，它们是免疫细胞之间相互交流的关键组成部分。阻断CD40L还能增加淋巴细胞向 ...

糖尿病，尤其是1型糖尿病（T1D），一直是一个困扰全球数百万患者的慢性疾病。许多患者每天需要注射胰岛素来控制血糖水平，这不仅给生活带来了不便，还伴随着一系列潜在的健康风险。那么，有没有可能让这些患者彻底摆脱胰岛素呢？最近的一项研究或许为我们带来了答案。 想象一下，如果有一种方法能够让糖尿病患者不再依赖胰岛素，那将是一个多么令人振奋的消息！近日，Eledon Pharmaceuticals公司公布了 ...

Tegoprubart works against the CD40 ligand and that is to block the ... Taking it one step further than this, the inhibiting of CD40L also turns lymphocytes into T regulatory Cells [Tregs], which ...

Abiprubart (anti-CD40 monoclonal antibody inhibitor of CD40-CD154 interaction) Kiniksa is enrolling and dosing patients in a Phase 2b clinical trial designed to evaluate the efficacy and safety of ...